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Dexamethasone (Dex) is a synthetic glucocorticoid that has anti-inflammatory and
immunosuppressant effects and is used in several conditions such as asthma and
severe allergy. Patients receiving Dex, either at a high dose or for a long time, might
develop several side effects such as hyperglycemia, weight change, or osteoporosis
due to its in vivo non-selectivity. Herein, we used liquid chromatography-tandem
mass spectrometry-based comprehensive targeted metabolomic profiling as well as
radiographic imaging techniques to study the side effects of Dex treatment in rats.
The Dex-treated rats suffered from a ∼20% reduction in weight gain, hyperglycemia
(145 mg/dL), changes in serum lipids, and reduction in total serum alkaline phosphatase
(ALP) (∼600 IU/L). Also, compared to controls, Dex-treated rats showed a distinctive
metabolomics profile. In particular, serum amino acids metabolism showed six-fold
reduction in phenylalanine, lysine, and arginine levels and upregulation of tyrosine
and hydroxyproline reflecting perturbations in gluconeogenesis and protein catabolism
which together lead to weight loss and abnormal bone metabolism. Sorbitol level
was markedly elevated secondary to hyperglycemia and reflecting activation of the
polyol metabolism pathway causing a decrease in the availability of reducing molecules
(glutathione, NADPH, NAD+). Overexpression of succinylacetone (4,6-dioxoheptanoic
acid) suggests a novel inhibitory effect of Dex on hepatic fumarylacetoacetate hydrolase.
The acylcarnitines, mainly the very long chain species (C12, C14:1, C18:1) were
significantly increased after Dex treatment which reflects degradation of the adipose
tissue. In conclusion, long-term Dex therapy in rats is associated with a distinctive
metabolic profile which correlates with its side effects. Therefore, metabolomics based
profiling may predict Dex treatment-related side effects and may offer possible novel
therapeutic interventions.
Keywords: pharmacometabolomics, dexamethasone, glucocorticoids, mass spectrometry, metabolomics,
osteoporosis, rats, side-effects
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INTRODUCTION
Dexamethasone (Dex) is a non-selective glucocorticoid (GC)
drug that is widely used for immunological, allergic, and
inflammatory diseases treatment via the activation of the nuclear
glucocorticoid receptors (GRs). GRs are widely expressed in the
body, and they promote the expression of several genes that
regulate multiple metabolic pathways, such as inflammation,
and glucose, lipid, and bone metabolism (Rafacho et al., 2014;
Wu et al., 2014). Dex administration can cause several side
effects, either at high doses or after long-term use. Insulin
resistance and hyperglycemia, weight change, and hyperlipidemia
are considered the primary adverse metabolic changes strongly
associated with Dex administration (Hopkins and Leinung,
2005). Furthermore, the degree of osteoporosis and bone loss
that stem from Dex depends on age, weight, gender, and the
duration of drug use (Reid, 2000). In addition, steroid psychosis
(e.g., mania, hallucinations, and delusions) is a typical irreversible
central nervous system (CNS) side effect associated with the
Dex treatment and other steroids (Ciriaco et al., 2013). Muscle
atrophy is mediated via activation of the cellular proteolytic
system (mainly the ubiquitin-proteasome system); which results
in the accumulation of TRIM63 and FBXO32 in muscle, in
response to Dex (Morimoto et al., 2015). These adverse effects are
more likely to occur in susceptible individuals, such as pregnant
women, obese subjects, or diabetic patients (van Raalte et al.,
2009).
Osteoporosis is also a known side effect of long-term therapy
with steroids. Multiple biomarkers useful for monitoring bone
health such as related bone enzymes and bone mineral density
(BMD) are commonly used in clinical practice. Osteocalcin (OC),
also known as bone gamma carboxyglutamic acid protein
(BGLAP) is a widely expressed protein linked to the bone
formation and has an essential role in bone mineralization given
its ability to bind calcium and promote osteoblast differentiation
which is indicated by alkaline phosphatase (ALP) activity.
However, ALP is a non-specific biomarker for bone disorders in
which serum ALP level and bone density are decreased due to
impaired osteogenesis (Brzoska and Moniuszko-Jakoniuk, 2004).
Pharmacometabolomic studies measure metabolites in an
individual’s biological matrices to predict and evaluate the
metabolism of pharmaceutical compounds and understand
a drug’s pharmacokinetic profile (Jacob et al., 2017). Also,
they measure within an individual the metabolic level change
following a specific drug administration, to monitor its
effects on individual metabolic pathways (i.e., in line with
pharmacodynamics). Dex induces the metabolic changes in a
complicated way involving several metabolic pathways. In a
recent comprehensive metabolomic study based on a single dose
exposure to Dex in healthy human volunteers, multiple metabolic
changes predicted the side effects related to this exposure (Bordag
et al., 2015). However, this prediction could not be validated
without observing the actual side effects, which only can be done
in an animal model. In this study, we evaluated the metabolomics
profile (Metabotype) in an established animal model with known
Dex related side effects. This holistic approach may lead to a
better understanding of the mechanisms of intentional (as a
nominated target of the compound) or unintentional (as side




Sprague-Dawley (SD) rats were obtained from the Department
of Comparative Medicine at King Faisal Specialist Hospital
and Research Center (KFSHRC) (Riyadh, Saudi Arabia).
Isoflurane for anesthesia during blood collection and sacrificing
was purchased from Piramal Critical Care (Bethlehem, PA,
United States). Dexamethasone phosphate, solvents, and other
standard chemicals for metabolomics were obtained from Sigma–
Aldrich (St. Louis, MO, United States). The reagents for
the routine chemistry analyzer were purchased from Roche
(Kaiseraugst, Switzerland), β-crosslaps (β–CTx) ELISA kit from
Abbexa (Cambridge, United Kingdom), osteocalcin ELISA kit
from Elabscience Biotechnology (WuHan, China).
Metabolite standards and reagents were obtained from
Sigma Chemicals (St. Louis, MO, United States) at a minimum
purity of 98%. Pterin (2-Amino-4-hydroxypteridine) and
L-Monapterin were purchased from Schricks Laboratories
(Postface, Switzerland). Isotope-labeled internal standards:
2-Amino 1,6-Hexandioc-D3, Guanosine-15N5, Inosine-
15N4, D-Fructose(2-13C), Citric acid-D4, L-Citrulline-D7,
Adenosine-C13, Methylmalonic acid-D3, 2-Deoxyadenosine-
C13, Glucose–D7 were purchased from Cambridge Isotope, Inc.
(Woburn, MA, United States). Whereas Alanine-D4, Arginine-
D7, Aspartic acid-D3, Citrulline-D2, Glutamic acid-D5,
Leucine-D3, Methionine-D3, Ornithine –D6, Phenylalanine-D5,
Tyrosine-D4, Valine-D8, C0-Carnitine-D9, C2-Carnitine-D3,
C3-Carnitine-D3, C4-Carnitine-D3, C5-Carnitine D9, C6-
Carnitine-D3, C8-Carnitine-D3, C10- Carnitine-D3, C12-
Carnitine-D3, C14- Carnitine-D3, C16- Carnitine-D3, C18-
Carnitine-D3 were purchased from ChromoSystems (Grafelfing,
Germany). All organic solvents and water used in sample and
mobile phase preparations were LC-MS/MS grade and obtained
from Fisher Scientific (Fair Lawn, NJ, United States).
Animal Model
The animal study was carried out according to a protocol
approved by the animal ethics committee at KFSHRC (approval
number 2150016). To eliminate the potential effect of female
sex hormones on bone metabolism, two groups of male SD rats
(Age: 6–8 weeks, weight: 200–250 g) were used in this study.
All rats were kept under standard environmental conditions
with regulated temperature (20–24◦C), humidity (45–50%) and
12 h/12 h light/dark cycle with free access to food and water.
Rats were randomly separated into two groups (n = 10 each).
The Dex and control (Ctrl) groups were injected intramuscularly
with 2.5 mg/kg twice a week for 14 weeks with Dex and
normal saline, respectively to induce most of the Dex side
effects as suggested by (Liu et al., 2012). The animals were
housed in the Department of Comparative Medicine’s animal
facility at KFSHRC, where clinical phenotype was monitored on
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a weekly basis such as animal’s weight using an animal scale,
blood sugar using glucometer GlucoCheckTM. Blood samples
for routine work were collected from the tail vein once every
other week, while the animals were anesthetized using isoflurane
2–3% inhalation in the CO2 chamber. Total serum ALP and
lipid profile were measured upon sample collection using
routine chemistry analyzer (Reflotron R© Plus Analyzer) (Roche,
Switzerland). LDL was calculated using Friedewald Formula
(FF) [LDL (mg/dL) = TC - HDL - TG/5.0] (Friedewald et al.,
1972). Blood samples were collected into heparinized tubes and
immediately centrifuged at 4,500 rcf for 10 min. Serum was
transferred to a clean tube and stored at −80◦C until the end
of experiment for further analyses. The blood samples were
stored properly after snap-freezing the metabolism using liquid
nitrogen. Tibia and femur bones were collected after sacrificing
the rats for further bone experiments.
Bone Turnover Biomarkers
Measurements
As biomarkers for bone resorption and formation, respectively,
serum β-crosslaps (β-CTx) and osteocalcin (OC) levels were
measured in both study groups using ELISA-based kits.
Bone Micro-computerized Tomography
(µ-CT) Scan
Rat femur was fixed in 3.7% paraformaldehyde for 24 h and
analyzed by micro-CT (Skyscan, CT analyzer software, Bruker,
MA, United States) to determine BMD.
In Vivo Magnetic Resonance
Imaging (MRI)
MRI acquisitions were performed in a free-breathing imaging
protocol on a 4.7T Pharmascan 47/16 Bruker magnet interfaced
with Para-Vision 5.1 software (Bruker Biospin GmbH,
Rheinstetten, Germany) and operated at 300 mT/m and a
slew rate of 2700 mT/m/s. A transmission and reception
circularly polarized volume radio frequency coil (Bruker), with
an inner diameter of 60 mm, was used for good homogeneity
over the volume of interest.
Non-invasive MRI of the lung and abdominal organs (i.e.,
liver, spleen, and kidneys) were performed to assess whether the
treatment with Dex has induced any alterations or inflammatory
processes in the rats. Axial slices of 2 mm thickness were
acquired using susceptibility-weighted gradient echo sequence
with TR/TE = 300/3 ms, four averages, flip angle 30◦, and
234 × 234 µmin-plane resolution for a total acquisition time
of 5 min. Before imaging, a global shimming procedure was
performed to optimize the magnetic field over the imaging
volume of interest. An ultrapure water tube was positioned over
the body of the rate as an external reference to normalize the MRI
signal and allow measurement of contrast-to-noise ratio (CNR)
variation in the different regions of interests.
For studying the bones of treated animals, sagittal slices were
carefully positioned at the same location for all rats to encompass
the knee and the lateral femur and tibia. High-resolution images
with 1 mm thickness were acquired using a fast-spin echo (FSE)
rapid acquisition with a refocused echoes (RARE) sequence with
TR/TE = 2500/34 ms, RARE factor = 8, four averages, and
100 × 100 µm-plane resolution for a total acquisition time of
20 min.
Bone Fracture Test
After sacrificing, tibia bone was weighed as wet, decreased in
chloroform-methanol (2:1, v/v) for 48 h, and then dried at 120◦C
for 6 h. The dried bones were weighed again, and fracture forces
were tested by using fracture instrument H5KS (Tinius Olsen,
EUK). The instrument’s parameters were adjusted for stress range
200 MPa, 10% of displacement range, speed 10 mm/min, span
20 mm, and auto return off.
Metabolomics Studies
The LC-MS/MS-based metabolomics analysis was performed
using a recently developed and validated comprehensive targeted
method in our lab (Jacob et al., 2018). For the extraction of
the polar metabolome, one mL of cold extraction solvent (50%
acetonitrile/50% methanol) was added to 100 µL rat serum
samples containing an additional 10 µL of labeled internal
standards. The mixture was shaken at 1000 rpm for one h at
4◦C in a ThermoMixer (Eppendorf, Germany) (Abdel Rahman
et al., 2014). Following extraction, samples were spun down
at 14,000 rpm for 10 min at 4◦C, and the supernatant was
transferred to fresh tubes to be evaporated to dryness (∼1 h)
in a Savant SpeedVac concentrator (Thermo Fisher Scientific
Inc., CA). The dry extract was reconstituted in a mixture
consisting of the mobile phase and placed in the autosamplar
at 4◦C for analysis. In this LC-MS/MS method, we used an
Acquity UPLC-XEVO TQD tandem mass spectrometer (Waters
Corporation, United States). Analytes were separated by reversed
phase chromatography using Acquity UPLC C18, 1.7 µm,
2.1 mm × 100 mm column (at ambient temperature). Each
sample was analyzed twice; in positive and negative ionization
modes. In positive mode analysis, the mobile phase consisted of
(A) 0.1% acetic acid and (B) 50% acetonitrile (ACN) and 50%
Methanol (MeOH). The mobile phase, for the positive mode,
was ramping from 2 to 95% for 10 min, held for 1 min at 95%
then mobile phase A was ramped back to 2%, to regenerate the
column for the next run. In negative mode, the mobile phase was
composed of (A) 0.1% tributylamine (TBA), 0.03% acetic acid,
10% MeOH and (B) 100% ACN. Subsequently, mobile phase for
negative mode was ramping from 5 to 70% for 13 min, held for
1 min at 70% and then the mobile phase A ramped back to 5%, to
regenerate the column for the next run. The samples were run
in the positive mode first and then run on the negative mode
with an intermediate automated washing step to avoid any sample
carryover. The total run time for each sample in each mode was
15 min at a flow rate of 0.3 mL/min. The samples were stored in
the autosampler at 4◦C, and the injection volume was 10 µl.
The targeted compounds which were prepared in 50%
methanol (400 µM) were infused into XEVO TQD (Waters
Corporation, United States) for optimization. The source
and desolvation temperatures were set at 150◦C and 250◦C,
respectively, while the desolvation gas was set at 500 L/h to tune
molecules in both (positive and negative) polarity modes. The
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specific tuning parameters, such as ionization polarity, precursor
and product ions, cone voltage and collision energy (CE) were
obtained for each analyte. The eluted metabolites were analyzed
under the optimal MS conditions listed in Supplementary
Table S1 using electrospray ionization. The cone voltage ranged
from 18 to 170 V, and the collision energy ranged from 7 to 65 eV.
Common MS parameters were the same as the tuning conditions
described above except the desolvation temperature and gas flow
which were 500◦C and 1000 L/h, respectively.
A chromatographic method was developed to accommodate
the best baseline separation for the targeted metabolites within
15 min of retention time; the gradient started at injection (zero
dead volume). A mixture of all of these compounds was used
to prepare a wide range of calibration curve (1–1000 nM) and
a set of analytical quality control (QC) samples (25, 250,750 nM).
The MS was maintained using a calibration kit and protocol
as recommended by the manufacturer (Waters Corporation,
United States).
Data and Statistical Analysis
The raw data was analyzed using MetaboAnalyst software version
3.0 (McGill University, Montreal, QC, Canada). Features with
more than 50% missing values were removed, while others with
missing values were replaced with small values (half of the
minimum positive values in the original data) assumed to be
above the detection limit. The data was then normalized to the
equivalent internal standard’s area under the peak, and then to
the sample total sum to ensure normal distribution. To adjust for
the differences among the study samples, data log transformation,
and Pareto scaling approaches were used to make individual
features more comparable. As the vast majority of the study
analytes were Gaussian distributed, unpaired two-tailed Student’s
t-test was used to compare the differences between two study
groups (treated, non-treated), where the significance levels for
metabolomics data were considered at a false discovery rate
(FDR) corrected p-value < 0.05, and values were presented as
mean ± SEM. The Sample Size Calculator for designing clinical
research1 was used for the Mean-effect size analysis which was
performed along all statistical analyses.
The chemometric analysis was carried out using principal
component analysis (PCA) and orthogonal partial least-squares
projection to latent structure-discriminant analysis (orthPLS-
DA) (Xia and Wishart, 2016). OPLS-DA is a supervised
multiple regression analysis for identifying the discrimination
between different datasets. The bar-graphs were generated using
Graph Pad Prism V. 6 (Xia et al., 2009, 2012). The FDR-
corrected p-values are represented on the figures as 0.0001 (∗∗∗),
0.001 (∗∗), and 0.05 (∗). The statistically significant features
between the study groups were used for pathway analysis
and molecular mapping. Metabolic enrichment and pathway
analyses were based on MetaboAnalyst2. The Rattus norvegicus




used for large-scale network analysis and the visualization of the
integrated metabolism pathways (Shannon et al., 2003).
RESULTS
Phenotypic Changes Associated with
Dex Treatment
The effects of Dex on body weight change, blood glucose level,
and lipid profile were monitored during the experiment. The
age-dependent body weight of the control (Ctrl) group increased
as expected; however, within the Dex-treated group, it was
significantly reduced by ∼20% (Figure 1A). Additionally, the
average total weight was also significantly reduced (p< 0.0002) in
the Dex-treated group, by 67.99± 14.06 g (Figure 1B). The blood
glucose level in the Dex-treated group was substantially higher
than in the Ctrl group (Figure 1C). In line with previous studies
(Divertie et al., 1991; Plonne et al., 2001; Bruder et al., 2004), there
were changes in the lipid profile of the Dex-treated rats, relative
to those in the Ctrl group. The TG level changed significantly in
the Dex group (p< 0.0001), and was the most-affected parameter
in the profile; meanwhile, total cholesterol and HDL remained
almost unchanged in the Dex-treated group, compared to the
Ctrl group. On the other hand, LDL was markedly reduced in
the Dex-treated group relative to the Ctrl group (p < 0.001)
(Figure 1D).
Soft-Tissue MRI and Autopsy
Examinations
During animal sacrifice, some soft-tissue masses and changes
were observed in different organs, mainly in the Dex-treated
group. These included grossly hemorrhagic lung and liver, and
kidney cysts as well as smaller organs than those in the Ctrl group.
MRI was the technique of choice in exploring these observations
in the lung, liver, kidney, spleen, and bone tissues, in both the
Dex-treated and Ctrl groups. MRI images of the lung, liver,
kidney and spleen tissues showed no changes between the two
groups, and there was no radiographic evidence of inflammation
or masses within these organs (Figures 1E,F).
Bone Turnover Related Side Effects
The effects of Dex treatment on bone tissue and on bone
turnover were evaluated, using a variety of physical, chemical,
and biochemical approaches. MRI of the knee, lateral femur and
lateral tibia showed a deformity and a change in the structure
and borders of the area (Figure 2A). The tibia dry-weight was
measured and found to be reduced significantly in the Dex-
treated group (P < 0.0005) compared to Ctrl (Figure 2B). These
results were concordant with the femur weights (data are not
shown). Also, there was a significant reduction in tibia-diameter
(p < 0.0017) and length (p < 0.0448) due to Dex treatment
(Figures 2C,D). To determine the bone density and resulting
osteoporosis, BMD was measured ex vivo in tibia using µ-CT
scan. Where a significant reduction in BMD (p < 0.0039) was
identified in the Dex group compared to Ctrl (Figure 2E). These
results are in agreement with the fracture force test that was
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FIGURE 1 | Dexamethasone effect on rats phenotypes. (A) The difference in weight between Ctrl and Dex treated groups during the 16 weeks period, a reduction in
age-dependent increase in weight is observed in Dex treated group compared to Ctrl. (B) A significant reduction in total weight of Dex treated group compared to
Ctrl (p-value 0.0002). (C) Significant effect of Dex treatment on blood glucose level (p < 0.05). (D) Effect of Dex on lipid profile (Cholesterol, Triglycerides (TG),
High-Density Lipoprotein (HDL), Low-density lipoprotein (LDL)) in Dex treated rats compared to Ctrl. No significant effect (ns) was found on total cholesterol and HDL
levels (p > 0.05); TG levels were significantly increased in Dex group (p-value 0.0001) while LDL levels were significantly decreased (p-value 0.001). p-values were
calculated using unpaired student’s t-test, n = 10/group. (E) Changes in soft tissues in Dex treated rats. (F) Soft tissue MRI image (left) lung, (middle) liver, and (right)
kidney and spleen in the Ctrl group and Dex treated groups.
performed on pre-treated dried tibias using H5KS (Tinius Olsen,
EUK), where the fracture force required to break up the tibia was
significantly lower (p< 0.0187) in Dex group compared to Ctrl as
shown in Figure 2F. In Ctrls, the fracture force ranged from 50 to
60 N compared to an average of 30 N in the Dex group indicating
greater than 50% reduction.
Bone metabolism has two arms; bone formation
(osteogenesis) and resorption. Several biomarkers were used
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FIGURE 2 | Effects of Dex treatment on bone tissues. A representative MRI of knee and lateral femur and tibia in Ctrl (left), and Dex (right) shows a bone deformity in
Dex treated animals compared to Ctrl (A). There was a significant reduction in dry bone weight of tibia (B), tibia diameter (C), tibia length (D) and (femur) bone
mineral density measured by µ-CT (E), where the p-values were <0.0005, <0.002, <0.05, and <0.0001, respectively. Tibia bone fracture force was significantly
reduced in Dex group (p < 0.02) compared to Ctrl (F). Serum levels of alkaline phosphatase (ALP) (G) and osteocalcin (OC) (H) are significantly reduced in Dex
treated animals (p < 0.02 and <0.002 respectively) while β-crosslaps (β-CTx) levels were not (p > 0.2) (I).
to evaluate the role of Dex in both processes. Serum levels of
ALP and OC, as bone formation biomarkers, were reduced
significantly in rats treated with Dex (p< 0.0115, and p< 0.0019,
respectively) as shown in Figures 2G,H. The average of OC
levels in Ctrl and Dex groups were found to be 140.0 ng/ml
and 60.0 ng/ml, respectively, which is equivalent to more
than 50% reduction. Serum levels of β-crosslaps (β–CTx), a
bone resorption biomarker used clinically and in therapeutic
monitoring were not changed significantly between the two
groups (p < 0.1323) as shown in Figure 2I. This suggests
that Dex selectively regulates (in an unknown mechanism)
osteogenesis rather than bone resorption.
Serum Metabolomics Abnormalities in
Dexamethasone Treated Rats
A library of 225 targeted and clinically relevant metabolites
was obtained from commercial sources and used to optimize
the LC-MS/MS instrument in multiple reactions monitoring
(MRM) mode. The compound specific chromatographic and
mass spectrometric parameters such as retention time (RT),
precursor ion (Q1), product ion (Q2), collision energy (CE) and
cone voltage are summarized in Supplementary Table S1. This
metabolomics method was validated following internationally
accepted guidelines.
The metabolites area under the peak was normalized
to the equivalent internal standard’s area under the peak,
and the area ratio was normalized to the sample total
sum to make sure all detected metabolites are within the
normal distribution. The data scale was log-transformed,
and the overall distribution scaled by Pareto-Scaling (mean-
centered and divided by the square root of the standard
deviation of each variable) showed the intensities of most
of the features within the normal Gaussian distribution.
Box plot analysis displayed only 50 features due to space
limitation while density plot depends on all samples
(Supplementary Figure S1).
The detected metabolites visualized in the volcano plot
(Figure 3A) were evaluated using t-test FDR-corrected p-value
(y-axis) and fold change (FC) (y-axis) analyses. The significant
features in the volcano plot (Figure 3A), are the ones that
pass FC and FDR-corrected p-value thresholds, 1.2 and 0.05,
respectively. Features shown in pink dots in the upper right and
left corners of the plot, respectively represent significantly down-
regulated or up-regulated metabolites upon Dex treatment.
Glutamine, lysine, alanine, cysteine, leucine, 4,6, Dioxoheptanoic
acid (succinylacetone), sorbitol, cAMP, CDP, valine, and a
few others represent the most important features that were
significantly changed (p < 0.05) (Figure 3A and Supplementary
Table S2).
The orthogonal partial least-squares projection to latent
structure-discriminant analysis (orthPLSDA), unsupervised
multivariate analysis, shows the separation between Ctrl and Dex
groups with Q2 = 0.959. The spacing between the two groups
represents the degree of biochemical perturbation that occurred
in Dex group compared to Ctrl (Figure 3B). The corresponding
loading plot (Figure 3C) is used to identify biomarkers, where
the features furthest from the origin are changed in their level
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FIGURE 3 | Dexamethasone effects on serum targeted metabolites. (A) Important features selected by volcano plot analysis with fold change threshold (x-axis) at
1.2 and t-tests threshold (y-axis) at 0.05. Pink circles represent features above the threshold. Please note both p-values and fold changes are log10 and log2
transformed, respectively. The further the feature’s position is away from the origin point (0,0), the more significant it is. (B) Separation of Ctrl and Dex groups using
OPLS-DA score plot analysis (Q2 = 0.959). The t[1] and [1] values represent the score of each sample in principal components 1 and 2, respectively. (C) Loading
S-plot generated by OPLS-DA analysis. The x-axis represents a measure of the relative abundance of ions, while the y-axis shows the correlation of each ion to the
model. (D) Heatmap analysis showing the top significantly enriched features from t-test in Ctrl (red) and Dex treated (green) groups. (E) Serum levels of several
acylcarnitines (C18:1, C14:1, C6DC, C12, OH-C5, C6, C4) were significantly increased (p < 0.005) in the Dex treated animals.
significantly between the two groups, and they may be considered
potential biomarkers of different side effects of Dex treatment.
The most significant features, based on t-test, are visualized on
a heatmap (Figure 3D), where the metabolites were segmented
and clustered hierarchically based on the changing similarity
across the study groups. The amino acids profile showed multiple
abnormalities suggesting differential effects for Dex exposure.
Several serum amino acids were down-regulated (p < 0.0001)
in contrast to hydroxyproline, tyrosine, and tryptophan levels
which were significantly increased as shown in Figures 4C,D.
Asparagine, cystathionine, homocysteine, and 3-methylhistidine
were not significantly altered under the study condition.
Metabolomics Pathway Analysis
Pathway analysis was performed on the featured metabolites
to identify the most relevant pathways involved in Dex
administration. Amino acyl-tRNA biosynthesis is most
significantly altered in this study which is a reflection of
widespread perturbations in amino acids metabolism. Arginine
and proline metabolism, pyrimidine metabolism, alanine,
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FIGURE 4 | Analysis of metabolic pathways. (A) Summary of pathway analysis for the most relevant pathways involved under experiment conditions.
(B) Tryptophan-kynurenine metabolism pathway. Dexamthesaone inhibits kenureninase which causes accumulation of kynurenine, 3-hydroxy-kenurenine, tryptophan
and secondarily serotonin (5-hydroxytryptamine). Dex treatment causes significant elevation in serum levels of tyrosine (C) and hydroxyproline (D) and significant
reduction in phenylalanine, lysine and arginine.
aspartate and glutamate metabolism, nitrogen metabolism,
branched chain amino acids (valine, leucine, and isoleucine)
biosynthesis were the most significantly enriched pathways
(P < 0.05) with different impacts as shown in Figure 4A.
Conversely, tryptophan and kynurenine levels were increased,
in Dex group, where these metabolites are involved in bone
turnover processes (Yadav et al., 2008; Liu et al., 2012).
Tryptophan is partially catabolized through the kynurenine
pathway which produces alanine as a byproduct (Figure 4B). In
this study, levels of phenylalanine and tyrosine were decreased,
and increased, respectively in the Dex-treated group (Figure 4C),
both of which are implicated in osteoporosis (Wu et al., 2015).
Hydroxyproline is another amino acid product of collagen
breakdown, and it might be considered as a bone resorption
biomarker, which was markedly elevated as shown in Figure 4D.
DISCUSSION
Dexamethasone is one of the GC drugs that has many potentially
serious adverse effects when used in large doses or long-term.
(Harris et al., 2015) Selecting the right model for studying the
drug side effect is very critical, as many factors could affect
the side effects profile such as age, gender, race, pregnancy,
breastfeeding, alcohol intake and impaired renal function. In
humans, both the very young and very old patients are more
vulnerable to such adverse reactions than other age groups. In
this study, we intended to minimize the potential impact of
these factors by using the male SD rat model that has been
used previously to study the Dex related side effects. The clinical
phenotypic and metabolic changes (metapotypes) associated with
Dex were mapped in rats, where the effect size analysis showed
that this model has 80% power to detect an effect size of
1.325. Rearrangement of fat deposition, known clinically as a
buffalo hump and moon face, muscle atrophy and high water
retention increase the body weight in humans treated with
Dex or steroids in general (Chong et al., 1994; Cheskin et al.,
1999; Brotman et al., 2005; Cristancho and Lazar, 2011). Herein,
different from humans, age-related weight gain was observed to
be severely reduced in rats treated with Dex, due to a reduction
in food intake, appetite, and energy. These effects were probably
mediated by the altered expression of specific genes that are
involved in the synthesis of adipose tissues such as (Ob) gene (De
Vos et al., 1995; Askari et al., 2005; Morimoto et al., 2015; Wu
et al., 2017). Muscle atrophy is another factor that contributes to
weight gain reduction due to inhibition of protein synthesis and
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induction of its degradation as reflected by the amino acid profile
as shown in Figures 4C,D. The reduction in bone and other
organs weight and size suggested a role for Dex in modulating
overall growth which may lead to severe reduction in age-related
development (Wu et al., 2017).
The Glu level was elevated in Dex-treated group, where
fluctuations in postprandial glucose levels may ultimately lead
to diabetes mellitus as a side effect of Dex after long-term use
(Hong et al., 2014). Dex is known to play an inhibitory role
in insulin signaling in different tissues (Ferris and Kahn, 2012;
Wei et al., 2014), where the expression of insulin receptor (IR) is
affected due to changes in protein tyrosine kinase by GCs (Caratti
et al., 2015). Also, a reduction in β-cells insulin production
explains the development of insulin resistance (Biddinger and
Kahn, 2006). Gluconeogenesis is another contributing pathway in
glucose synthesis, which might be enhanced by Dex as suggested
by the elevation of serum levels of several gluconeogenic amino
acids and severe weight loss complicated by the hyperglycemia
mediated protein degradation (Mazziotti et al., 2011; Rafacho
et al., 2014). Hyperglycemia is well known to lead to sorbitol
accumulation via the activation of the polyol pathway as observed
in Figures 3A,D.
Abnormal lipid profiles and dyslipidemia are known to occur
in animals and humans after Dex treatment, where the total
cholesterol and TG serum levels are elevated (Bruder et al., 2004).
Dex enhances the secretion and reduces the transcription of
lipoprotein lipase (LPL) enzyme from liver and adipose tissue,
respectively, which consequently reduces the TG metabolism and
increases its level in serum (Julve et al., 1996). This lipid profile is
in agreement with the level of fatty acids (FA) as shown in the
acylcarnitines profile in Figure 3E, where several acylcarnitines
C18:1, C14:1, C6DC, C12, OH-C5, C6, and C4 were found to
be significantly increased in Dex group compared to Ctrl. The
Dex role in catalyzing the butyrylcholinesterase (BuChE) enzyme
activity supports the animal lipid profile (Lucic Vrdoljak et al.,
2005). BuChE controls the choline esters hydrolysis, which is
found to be decreased in plasma after Dex treatment (Lucic
Vrdoljak et al., 2005). While the exact mechanism by which Dex
treatment alters HDL levels is not well known, in a rat model,
Dex reduced the activity of LPL and increased the activity of
lecithin:cholesterol acyltransferase (LCAT), an enzyme which can
convert free cholesterol to cholesteryl ester, which then enhances
the production of HDL (Jansen et al., 1992). Although the effect of
Dex on the lipid profile depends on many factors such as dose and
duration, as well as genetic variations and environmental factors
(Ross and Marais, 2014), in this study, the dose frequency and
length of exposure to Dex were sufficient to maintain both total
cholesterol and HDL levels within the normal range, but increase
the TG and decrease the LDL levels significantly.
A balance between bone formation and resorption is an
important mechanism that maintains healthy bone structure
and function. Osteoporosis, a reduction in BMD, is a crucial
side effect of Dex, where the therapeutic and supratherapeutic
doses of Dex reduce bone formation and resorption, respectively
(Caniggia et al., 1981; Laan et al., 1993; Hansen et al., 1999;
Suzuki, 2015). Physical reduction in bone weight and size due
to Dex treatment are likely mediated via metabolic changes in
bone tissues. Several mechanisms are involved in Dex ability to
change bone tissue metabolism (Liu et al., 2015). Dex suppresses
the adrenal glands and reduces the sex hormones production
which inhibits osteoblast activity (Xia et al., 2014). The osteoblast
activity is also regulated by growth hormone and insulin-like
growth factor, muscle atrophy and myopathy (Silvestrini et al.,
2000). Previously, in agreement with our findings, a significant
reduction in BMD, bone mineral content, and bone surface area
were reported in rats injected with Dex for 12 weeks, as well
as a reduction in bone-weight (Ren et al., 2015). Bone porosity
and bone strength were reported to be increased and decreased
respectively in an animal model after GC use (McIlwain, 1991)
which supports our finding of the significant reduction in fracture
force in Dex group. In addition, abnormalities on bone MRI
examination are expected, where a high dose of GCs lead to
thinning and perforation of trabeculae (Ito, 2014). MRI of the
knee, lateral femur and tibia in Dex-treated rats showed bone
deformity.
Signs of osteoporosis were physically apparent in this study
as seen in the form of changes in bone weight, volume, strength,
bone deformity, and BMD. Changes in bone turnover biomarkers
were considered confirmatory findings of the metabolic changes
in bone tissue. Changes in OC serum level correlate with bone
turnover, where the reduction in serum levels indicates a loss in
bone formation (Liu et al., 2012). The bone specific-ALP isozyme
is another bone remodeling biomarker (Halling Linder et al.,
2013). Inborn errors of metabolism such as hypophosphatasia
and Wilson disease, malnutrition, zinc deficiency as well as some
drugs are known causes of reduced ALP levels and impaired
bone formation via inhibition of osteoblast activity (Wu et al.,
2014). An elevation in β-crosslaps (β-CTx) serum level indicates
bone resorption. Enhancement of Lysophosphatidylcholines
(C16:0LPC, C18:0LPC, C18:1LPC and C18:2LPC), tryptophan,
and phenylalanine are known to occur in serum due to Dex
administration in rats (Huang et al., 2014). Elevation of LPC
level due to Dex will enhance the production of reactive oxygen
species (ROS) generated by osteoclasts (Cristancho and Lazar,
2011). ROS under normal conditions lead to oxidant stress
which increases bone resorption, but natural antioxidant defense
mechanisms will terminate this stress (Askari et al., 2005).
If this is insufficient, then more bone loss and lower BMD
will occur (Hong et al., 2014). In this study, the anti-oxidant
glutathione was not significantly differentially expressed, which
probably contributed to osteoporosis. However, the full anti-
oxidants profile was not evaluated. In osteoporotic rats, elevated
levels of LPC due to an imbalance between antioxidant–oxidation
processes may lead to increased carbonyl content and protein
oxidation (Harris et al., 2015). Several studies have shown
osteoporosis metabolic changes after Dex administration, where
alanine and serotonin (5-HT) are the decomposed and the
hydroxylated products of tryptophan, respectively (Mohammad-
Zadeh et al., 2008; Chabbi-Achengli et al., 2012; de Vernejoul
et al., 2012; Michalowska et al., 2015). Alanine levels in
osteoporosis have been reported to be reduced in a rat model
(Almon et al., 2005). Furthermore, other studies suggested an
inhibitory effect of 5-HT on bone formation with 5-HT reducing
proliferation of murine primary osteoblasts and inhibiting nitric
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TABLE 1 | Detailed pathway analysis of significantly differentially expressed metabolites.
Pathway Total Hits Raw p −Log(P) Impact
Aminoacyl-tRNA biosynthesis 67 10 3.08E-07 14.993 0
Arginine and proline metabolism 44 6 0.000187 8.5867 0.31604
Pyrimidine metabolism 41 4 0.008808 4.7321 0.08466
Alanine, aspartate and glutamate metabolism 24 3 0.012032 4.4202 0.26371
Nitrogen metabolism 9 2 0.013598 4.2979 0
Valine, leucine and isoleucine biosynthesis 11 2 0.020248 3.8997 0.66666
Phenylalanine, tyrosine and tryptophan biosynthesis 4 1 0.08029 2.5221 0.5
Glutathione metabolism 26 2 0.098895 2.3137 0.00573
Galactose metabolism 26 2 0.098895 2.3137 0.03644
D-Glutamine and D-glutamate metabolism 5 1 0.099369 2.3089 0
Biotin metabolism 5 1 0.099369 2.3089 0
Cysteine and methionine metabolism 28 2 0.11217 2.1878 0.09464
Cyanoamino acid metabolism 6 1 0.11806 2.1365 0
Glycine, serine and threonine metabolism 32 2 0.14 1.9661 0.29197
Taurine and hypotaurine metabolism 8 1 0.15434 1.8686 0.42857
Purine metabolism 68 3 0.16275 1.8156 0.05757
Aminoacyl-tRNA biosynthesis 67 10 3.08E-07 14.993 0
Arginine and proline metabolism 44 6 0.000187 8.5867 0.31604
Pyrimidine metabolism 41 4 0.008808 4.7321 0.08466
Alanine, aspartate and glutamate metabolism 24 3 0.012032 4.4202 0.26371
Nitrogen metabolism 9 2 0.013598 4.2979 0
Valine, leucine and isoleucine biosynthesis 11 2 0.020248 3.8997 0.66666
Phenylalanine, tyrosine and tryptophan biosynthesis 4 1 0.08029 2.5221 0.5
Glutathione metabolism 26 2 0.098895 2.3137 0.00573
Galactose metabolism 26 2 0.098895 2.3137 0.03644
D-Glutamine and D-glutamate metabolism 5 1 0.099369 2.3089 0
Biotin metabolism 5 1 0.099369 2.3089 0
Cysteine and methionine metabolism 28 2 0.11217 2.1878 0.09464
Cyanoamino acid metabolism 6 1 0.11806 2.1365 0
Glycine, serine and threonine metabolism 32 2 0.14 1.9661 0.29197
Taurine and hypotaurine metabolism 8 1 0.15434 1.8686 0.42857
Purine metabolism 68 3 0.16275 1.8156 0.05757
oxide release from mouse-derived osteoblasts (Ferris and Kahn,
2012). A recent study in osteoporosis rat model reported a
significant increase in tryptophan levels, where the catabolism of
tryptophan to alanine was interrupted, and the hydroxylation of
tryptophan to serotonin was enhanced (Almon et al., 2005).
Dexamethasone Related Metabotypes
Rat sera exposed to Dex were profiled using an LC-MS/MS-based
comprehensive targeted metabolomics approach developed by
our group (Abdel Rahman et al., 2013, 2014). The profile
suggested a significant perturbation in several pathways such
as amino acid metabolism, pyrimidine metabolism, nitrogen
metabolism, and other pathways as summarized in Table 1.
The conversion of protein to carbohydrate through
gluconeogenesis is stimulated by GCs which then promotes
the storage of carbohydrate as glycogen (Kaplan and Shimizu,
1963). The expression of several serum amino acids after Dex
administration was low due to its mobilization from protein
and its subsequent breakdown as a source of carbon during
gluconeogenesis. However, these animals could not mobilize
amino acids adequately, indicating that cortisol played a role
in the mobilization process (Christiansen et al., 2007). This
explains the severe reduction in age-dependent weight gain of
the Dex group as shown mainly in the markedly down-regulated
phenylalanine as a marker for overall protein breakdown
(Figure 4D). However, the amino acid profile in this animal
model was not similar to that observed in humans where
multiple amino acids (Ala, Met, Asn, Phe, Pro, and Ser) were
elevated after a single dose exposure to Dex, which reflected
protein degradation of skeletal muscle (Bordag et al., 2015).
In addition, this amino acid profile supported the phenotypes
of muscle atrophy and weight loss observed in these animals.
Muscle atrophy resulted from protein degradation, where Dex
systemic administration upregulates glutamine synthetase,
which enhances the production of the gluconeogenic amino
acid glutamine by promoting protein catabolism (Falduto et al.,
1989).
The regulation of insulin signaling and homeostasis are quite
complex and involve multiple molecules such as fatty acid
synthase (FAS) whose expression is stimulated by insulin which
leads to storage of excess glucose into adipocytes as fat (Mancia,
2014). SREBF1 is known to regulate cholesterol synthesis, where
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its expression in adipocytes along with FAS is inhibited by leptin,
a hormone which regulates food intake and fat metabolism
(Considine et al., 1997; Castillo et al., 2017). Dex stimulates leptin
release from adipocytes and reduces the expression of SREBPs
and FAS which then result in increased serum acylcarnitines
as shown in Figure 3E (Considine et al., 1997). Leptin also
regulates body weight by decreasing food intake, increasing
energy expenditure, and inhibiting fatty acid synthesis, which
explains the reduction in weight gain in the Dex group as shown
in Figure 1A. To support the role of Dex in regulating the
release of leptin from adipose tissue, the serum glucose level was
found to be increased significantly (p < 0.05) suggesting lower
levels of insulin. Increased lipolysis is indicated by the abnormal
post-Dex treatment serum lipids profile which showed elevated
acylcarnitines (such as C18:1, C14:1, C6DC, C12, HO-C5, C6,
HO-C4, and C4) which is indicative of increased free fatty acids.
Hydroxyproline, a major component of collagen and along
with proline they play a key role in its stability. It is
considered a urinary bone resorption biomarker which is
produced via collagen breakdown (Seibel, 2005). Elevated serum
hydroxyproline observed in this study reflects the effect of Dex on
collagen breakdown and induction of bone resorption but not to
a level sufficient to raise serum levels of β-CTx. Therefore, serum
hydroxyproline was a more sensitive marker that represents
bone resorption earlier than β-CTx. Coupled with a significant
reduction in OC level, this combination suggested the occurrence
of osteoporosis due to severe loss of bone formation with some
increase in bone resorption activity.
Tryptophan is partially catabolized through the kynurenine
pathway. In this study, tryptophan and kynurenine levels were
increased, while alanine (a downstream product) was decreased,
which suggested Dex mediated inhibition of kynureninase
causing a backlog and accumulation of tryptophan and
its hydroxylated product serotonin (5-HT) as shown in
Figure 4B. Serotonin, a biogenic monoamine, is an essential
neurotransmitter both in the central and peripheral nervous
systems and following its release, it is actively cleared from
synaptic clefts by SLC6A4. More recently, the emerging role of
serotonin in bone metabolism and health had been investigated
and clarified (Mohammad-Zadeh et al., 2008; Chabbi-Achengli
et al., 2012; de Vernejoul et al., 2012; Yousri et al., 2017).
Serotonin appears to have an inhibitory effect both on bone
formation as well as resorption by reducing proliferation of
murine primary osteoblasts (inhibiting nitric oxide release) and
decreased osteoclastogenesis respectively (Yadav et al., 2008).
In growing and mature tryptophan hydroxylase (Tph1−/−),
serotonin deficient knockout mice, bone resorption was markedly
reduced as evidenced by fewer osteoclasts, a phenotype that
could be rescued by rescued by adding serotonin (Chabbi-
Achengli et al., 2012). Liu et al. (2012) found the hydroxylation of
tryptophan to serotonin was increased in the osteoporotic model,
and tryptophan level was increased significantly, which reflects
negatively on the catabolism of tryptophan to alanine (Liu et al.,
2012).
The hepatic gluconeoneogenic enzyme tyrosine
aminotransferase (TAT), as well as tyrosine hydroxylase,
are glucocorticoid dependent enzymes which regulate tyrosine
content in the blood which had been suggested to be an index
of glucocorticoid action on metabolism (Williams et al., 1981;
Rass, 2010). Also, under certain conditions, glucocorticoids can
induce the expression of the hepatic phenylalanine hydroxylase
enzyme (Bristeau et al., 2001). Therefore, the dysregulation
of phenylalanine and tyrosine levels is probably the result of
these complex effects of Dex on various GC responsive hepatic
enzymes. Phenylalanine and tyrosine levels have been associated
with osteoporosis as through altering Ca homeostasis by
activating the Ca receptor, and reducing the level of PTH, which
initiates the process of demineralization and bone resorption
(Wu et al., 2015). The induction of phenylalanine hydroxylase
and increase in the downstream metabolic expression such as
the stress hormones (adrenaline and noradrenaline) activate
the hormone-sensitive lipase (LIPE) via cyclic AMP-dependent
protein kinase (PKA), which phosphorylates LIPE. The
increasing activity of LIPE supports the increased level of some
serum acylcarnitines.
As shown in Figures 3A,D, we observed overexpression of
succinylacetone (4,6-dioxoheptanoic acid), a tyrosine metabolite
which typically accumulates in patients with tyrosinemia
type 1 who have recessive mutations in the hepatic enzyme
fumarylacetoacetate hydrolase (FAH). This finding suggests a
novel inhibitory effect for dexamethasone on FH. Therefore,
dexamethasone and similar glucocorticoids should probably be
used with caution in human patients with tyrosinemia type 1.
Finally, animal studies have shown that dietary supplements
with certain amino acids, particularly L-lysine and arginine
promote Ca absorption (Civitelli et al., 1992), and accordingly
increase BMD, and serum OC. In postmenopausal women,
administration of arginine-lysine-glycerophosphoric acid-lactose
combination increased BMD and plasma osteocalcin, while
serum PTH and hydroxyproline levels were reduced suggesting
clinical benefit (Bellati and Liberati, 1994). These observations
and the perturbed amino acids metabolism suggest a possible
novel therapeutic interventional window to prevent or mitigate
the effects of steroid-induced osteoporosis and related side effects.
Further studies are necessary to validate these observations.
CONCLUSION
Dexamethasone side effects are associated with several metabolic
abnormalities, where LC-MS/MS-based metabolomic profiling
of rats sera suggests a significant perturbation in several
pathways involving mainly the metabolism of amino acid,
pyrimidine, and nitrogen. Collectively, these disturbances
strongly correlate with various known side effects such as reduced
weight gain, hyperglycemia, dyslipidemia, and abnormal bone
turnover found in our study. Significantly differentially expressed
metabolites (hydroxyproline, tryptophan, alanine, phenylalanine,
kynurenine, tryptophan, and tyrosine) identified in Dex-treated
rats may serve as biomarkers able to predict the development of
Dex related side effects. Longitudinal monitoring and evaluation
of these biomarkers over the course of exposure to Dex in
susceptible subjects will help determine their sensitivity and
reliability in the diagnosis, prognosis, and therapeutic response.
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Expanded untargeted metabolomics and lipidomics profiling will
also likely yield additional potentially useful biomarkers.
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